Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma
- 7 November 2014
- journal article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 101 (1), 46-51
- https://doi.org/10.1007/s12185-014-1694-8
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized StudyJournal of Clinical Oncology, 2013
- Clinical characteristics and prognostic factors of pulmonary MALT lymphomaEuropean Respiratory Journal, 2009
- Staging Non-Hodgkin LymphomaCA: A Cancer Journal for Clinicians, 2005
- Primary Pulmonary LymphomaThe Annals of Thoracic Surgery, 2005
- Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare diseaseEuropean Journal of Cancer, 2004
- Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT typeBlood, 2003
- MALT LymphomasHematology, 2001
- Primary non-Hodgkin’s lymphoma of the lungThe Annals of Thoracic Surgery, 2000
- Reactive pulmonary lymphoid disordersHistopathology, 1995
- Primary lymphomas of the lung: morphological, immunohistochemical and clinical featuresHistopathology, 1990